Pancreatic Cancer Research

ResearcherHiroshima UniversityActive in the last 2 years

Michiaki Unno

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-2145-6416; OpenAlex author ID A5086139902, A5111486566. Sources: OpenAlex.

Their work

Papers
147 (first author 3, last author 56)
Trials
0
Grants
0
Labs led
1
Collaborators
344
Papers, trials and grants by year

2011: 5 papers · 2012: 1 paper · 2013: 7 papers · 2014: 2 papers · 2015: 8 papers · 2016: 6 papers · 2017: 11 papers · 2018: 9 papers · 2019: 11 papers · 2020: 17 papers · 2021: 14 papers · 2022: 8 papers · 2023: 15 papers · 2024: 7 papers · 2025: 11 papers · 2026: 15 papers

Papers 50 of 147

  1. Duke Pancreatic Monoclonal Antigen Type 2 for Monitoring Carbohydrate Antigen 19-9 Nonexpressor Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2026.1810↗
  2. Survival Impact After Resection for Postoperative Recurrence or Metastasis of Pancreatic Ductal Adenocarcinoma Analyzed Using a Time-Dependent Cox Regression M… Co-author DOI 10.1002/jhbp.70054↗
  3. Mortality and cancer risk in patients with chronic pancreatitis in japan: insights into the importance of surveillance for pancreatic cancer. Co-author DOI 10.1007/s00535-025-02321-0↗
  4. Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study. Co-author DOI 10.1007/s00535-026-02432-2↗
  5. Neoadjuvant and adjuvant treatment for pancreatic ductal adenocarcinoma in patients over 80 years old based on a nationwide clinical database. Co-author DOI 10.1007/s00535-026-02480-8↗
  6. Histological treatment response to neoadjuvant chemotherapy predicts the survival outcomes of patients with resectable pancreatic cancer: validation of the Jap… Last author DOI 10.1007/s00595-026-03325-w↗
  7. Long-term outcomes of plastic versus metal stents for preoperative biliary drainage in pancreatic cancer: a nationwide propensity score-matched analysis. Co-author DOI 10.1016/j.gie.2026.05.032↗
  8. SMAD3 activation in pancreatic stellate cells correlates with PTGDR2 expression and favorable stromal features in pancreatic cancer. Last author DOI 10.1016/j.pan.2026.03.007↗
  9. Utility of longitudinal changes in CA19-9 for detection of pancreatic ductal adenocarcinoma in patients with benign pancreatic diseases. Co-author DOI 10.1016/j.pan.2026.10.007↗
  10. Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geria… Co-author DOI 10.1093/jjco/hyag055↗
  11. Clinical Statistics and Outcomes of Pancreatic Neoplasms in Japan: A Retrospective Cohort Study Using the Japan Pancreatic Cancer Registry. Co-author DOI 10.1097/mpa.0000000000002694↗
  12. Neoadjuvant Chemotherapy With Gemcitabine and S-1 Versus Upfront Surgery for Resectable Pancreatic Cancer: Results of the Randomized Phase II/III Prep-02/JSAP0… Co-author DOI 10.1097/sla.0000000000006730↗
  13. Clinicopathological Factors on Survival after Conversion Surgery for Unresectable Locally Advanced Pancreatic Cancer: A Nationwide Study by the Japanese Societ… Co-author DOI 10.1097/sla.0000000000007012↗
  14. Aso Visual Abstract: Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18555-4↗
  15. Predictive Factors for Occult Metastases in Clinically M0 Pancreatic Cancer: A Prospective Multicenter Analysis of Staging Laparoscopy. Last author DOI 10.1245/s10434-026-20728-8↗
  16. Clinical role of intraperitoneal chemotherapy in patients with pancreatic ductal adenocarcinoma concomitant with occult peritoneal dissemination: A multicenter… Co-author DOI 10.1002/ags3.70001↗
  17. Optimal treatment strategy for patients with pancreatic cancer having positive peritoneal cytology: A nationwide multicenter retrospective cohort study supervi… Co-author DOI 10.1002/jhbp.12074↗
  18. A case of FGFR2 fusion-positive pancreatic head tumor with difficult differential diagnosis between cholangiocarcinoma and pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s12328-025-02193-0↗
  19. Clinical importance of suspicious for malignancy compared to positive for malignancy in peritoneal cytology for surgically resected pancreatic cancer. Co-author DOI 10.1016/j.pan.2025.05.006↗
  20. Transcriptional regulation of ETV5 by mitogen-activated protein kinase via ETS-1 in human pancreatic cancer cells. Co-author DOI 10.1038/s41598-025-97166-1↗
  21. Preoperative Chemotherapy With Gemcitabine for Pancreatic Cancer Causes Zinc Deficiency. Last author DOI 10.1097/mpa.0000000000002396↗
  22. Local Recurrence and Survival Outcomes after Portal Vein/Superior Mesenteric Vein Separation without Resection Preceding Neoadjuvant Therapy for Pancreatic Duc… Last author DOI 10.1097/mpa.0000000000002503↗
  23. Three Molecular Developmental Pathways of Remnant Pancreatic Cancer After Resection: A Nationwide Project Study of Japan Pancreas Society. Co-author DOI 10.1097/sla.0000000000006444↗
  24. [Multidisciplinary treatment for unresectable pancreatic cancer]. Last author DOI 10.11405/nisshoshi.122.819↗
  25. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  26. Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-17988-1↗
  27. Rupture of ectopic varices of the ascending colon occurring after pancreatic cancer surgery: A case report and literature review. Co-author DOI 10.1002/deo2.255↗
  28. GFPT2 expression is induced by gemcitabine administration and enhances invasion by activating the hexosamine biosynthetic pathway in pancreatic cancer. Last author DOI 10.1007/s10585-024-10298-y↗
  29. Early tumor shrinkage as a prognostic predictor in chemotherapy-naïve patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemc… Co-author DOI 10.1016/j.pan.2024.07.006↗
  30. Deep learning predicts the 1-year prognosis of pancreatic cancer patients using positive peritoneal washing cytology. Co-author DOI 10.1038/s41598-024-67757-5↗
  31. Machine Learning of Histopathological Images Predicts Recurrences of Resected Pancreatic Ductal Adenocarcinoma With Adjuvant Treatment. Co-author DOI 10.1097/mpa.0000000000002289↗
  32. Evaluation of the Treatment Duration of Japanese Patients With Pancreatic Cancer in a Real-World Setting Using a Large Hospital Claims Database: The SUISEI Stu… Last author DOI 10.1097/mpa.0000000000002321↗
  33. A multi-institutional randomized phase III study comparing minimally invasive distal pancreatectomy versus open distal pancreatectomy for pancreatic cancer; Ja… Co-author DOI 10.1186/s12885-024-11957-9↗
  34. Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Soc… Co-author DOI 10.1002/cncr.34580↗
  35. Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical … Last author DOI 10.1002/jhbp.1282↗
  36. Features of T1 pancreatic cancer and validation of the eighth edition AJCC staging system definition using a Korean-Japanese joint cohort and the SEER database. Co-author DOI 10.1002/jhbp.1316↗
  37. Standard versus delayed initiation of S-1 adjuvant chemotherapy after surgery for pancreatic cancer: a secondary analysis of a nationwide cohort by the Japan P… Co-author DOI 10.1007/s00535-023-01988-7↗
  38. TWIST1 is a prognostic factor for neoadjuvant chemotherapy for patients with resectable pancreatic cancer: a preliminary study. Co-author DOI 10.1007/s00595-023-02655-3↗
  39. Expression of Corticotropin-Releasing Hormone and Its Receptors May Be Associated With Survival Rate in Pancreatic Cancer. Last author DOI 10.1016/j.gastha.2022.09.003↗
  40. Ral GTPase promotes metastasis of pancreatic ductal adenocarcinoma via elevation of TGF-β1 production. Co-author DOI 10.1016/j.jbc.2023.104754↗
  41. GATA6 and CK5 Stratify the Survival of Patients With Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy. Co-author DOI 10.1016/j.modpat.2023.100102↗
  42. Negative prognostic impact of sarcopenia before and after neoadjuvant chemotherapy for pancreatic cancer. Last author DOI 10.1016/j.pan.2022.11.010↗
  43. Clinical impact of multimodal treatment including chemoradiotherapy, conversion surgery and postoperative chemotherapy for borderline resectable and unresectab… Co-author DOI 10.1016/j.pan.2023.07.002↗
  44. Collagen XVII regulates tumor growth in pancreatic cancer through interaction with the tumor microenvironment. Co-author DOI 10.1111/cas.15952↗
  45. [Preoperative therapy for pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.120.639↗
  46. Reduced expression of phosphorylated ataxia-telangiectasia mutated gene is related to poor prognosis and gemcitabine chemoresistance in pancreatic cancer. Last author DOI 10.1186/s12885-023-11294-3↗
  47. CA19-9 With Two-stage Resection Is Useful for Conversion Surgery in PDAC With Synchronous Oligometastases. Last author DOI 10.21873/anticanres.16724↗
  48. [A Case of an Elderly Patient Who Underwent Conversion Resection for Pancreatic Cancer with Positive Peritoneal Cytology]. Last author PMID 36807179↗
  49. Levels of tumor markers CEA/CA 19-9 in serum and peritoneal lavage predict postoperative recurrence in patients with pancreatic cancer. Last author DOI 10.1002/ags3.12597↗
  50. What is the impact of zinc deficiency for pancreatectomies in patients with pancreatic ductal adenocarcinoma? Last author DOI 10.1016/j.pan.2021.12.006↗

Closest collaborators

The 25 strongest of 344 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masamichi Mizuma · 65 shared papers, 2013–2026 · strength 9.06
  2. Fuyuhiko Motoi · 77 shared papers, 2011–2026 · strength 7.36
  3. Kei Nakagawa · 40 shared papers, 2013–2025 · strength 4.87
  4. Sohei Satoi · 36 shared papers, 2011–2026 · strength 4.39
  5. Shuichi Aoki · 22 shared papers, 2013–2026 · strength 3.50
  6. Atsushi Masamune · 20 shared papers, 2013–2026 · strength 3.11
  7. Takanori Morikawa · 29 shared papers, 2011–2023 · strength 3.05
  8. Shimpei Maeda · 24 shared papers, 2011–2026 · strength 2.91
  9. Masahiro Iseki · 19 shared papers, 2017–2026 · strength 2.87
  10. Kyohei Ariake · 23 shared papers, 2017–2026 · strength 2.71
  11. Toru Furukawa · 12 shared papers, 2020–2026 · strength 2.09
  12. Daisuke Douchi · 12 shared papers, 2017–2026 · strength 2.03
  13. Masayuki Sho · 21 shared papers, 2014–2026 · strength 2.00
  14. Hiroki Yamaue · 23 shared papers, 2014–2026 · strength 1.97
  15. Tatsuo Hata · 17 shared papers, 2016–2023 · strength 1.94
  16. Kei Kawaguchi · 22 shared papers, 2012–2023 · strength 1.88
  17. Tsutomu Fujii · 13 shared papers, 2016–2026 · strength 1.83
  18. Tatsuyuki Takadate · 20 shared papers, 2011–2023 · strength 1.82
  19. Satoshi Hirano · 9 shared papers, 2022–2026 · strength 1.73
  20. Goro Honda · 20 shared papers, 2014–2026 · strength 1.70
  21. Manabu Kawai · 15 shared papers, 2015–2026 · strength 1.69
  22. Shinichi Egawa · 23 shared papers, 2011–2026 · strength 1.67
  23. Kenichiro Uemura · 17 shared papers, 2015–2026 · strength 1.66
  24. Ippei Matsumoto · 18 shared papers, 2014–2026 · strength 1.58
  25. Yoshifumi Takeyama · 8 shared papers, 2023–2026 · strength 1.51

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.